Jennewein Biotechnologie GmbH’s Capital Increase

Hogan Lovells has advised Jennewein Biotechnologie GmbH on its capital increase. The capital increase was executed with the participation of existing investors. Jennewein Biotechnologie is a science-based company in the field of industrial biotechnology and is specialized in the development of new production processes for scarce functional sugars. Human milk oligosaccharides (HMOs) represent one of […]

John Laing Group PLC: cession d’un portefeuille de trois projets éoliens en France

Norton Rose Fulbright, CMS Cameron McKenna Nabarro Olswang et De Gaulle Fleurance & Associés ont conseillé dans le cadre de l’opération John Laing Group PLC, un investisseur britannique actif et gestionnaire de projets d’infrastructures renouvelables, a finalisé la cession d’un portefeuille de trois projets éoliens en France. D’un montant de 30 millions d’euros environ, cette […]

Cenkos Securities plc’s £9.50 Million Secondary Fundraise For Arena Events Group plc

Osborne Clarke has advised Cenkos Securities plc on this deal. Cenkos Securities plc acted as nominated adviser and broker, on a secondary fundraise, by way of a placing with institutional investors and a separate subscription by a corporate investor, for Arena Events Group plc. Arena is a provider of temporary physical structures, seating, ice rinks, […]

Copenhagen Infrastructure Partners’ Portfolio Of Four German Offshore Grid Connections Acquisition

Watson Farley & Williams has advised Copenhagen Infrastructure Partners on this deal. Copenhagen Infrastructure Partners expanded its existing partnership with Dutch transmission system operator TenneT Holding B.V. (“TenneT”) regarding a portfolio of four German offshore grid connections with a total transmission capacity of c. 2.8 GW transmitting wind energy from the North Sea to Germany. […]

finnCap Ltd’s £14 Million Placing For Synairgen plc

Osborne Clarke has advised finnCap Ltd on the placing for Synairgen to accelerate potential COVID-19 treatment trial. Fieldfisher acted for Synairgen. Synairgen will use the fundraising to expedite an MHRA/HRA-approved trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients to potentially assist with the global outbreak of the virus, the manufacture of the SNG001 […]